English 
Español
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody.
Related Articles
-
UDIBI
Published: September 6, 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a...
-
UDIBI
Published: april 2nd, 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based Enzyme‐Linked Immunosorbent Assays...
-
UDIBI
Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis. SHOW MORE
-
UDIBI
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
-
UDIBI
Published: September 20, 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract...
-
UDIBI
Published: August 28, 2022 Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies More information
-
UDIBI
Published: September, 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer...
-
UDIBI
October 6, 2021 Increased survival in puppies affected by Canine Parvovirus type II using an immunomodulator as a therapeutic...
0 Comments
